Canada
Search    
Include All CSL Behring Country Sites

News Room

The most recent items of news in the Canadian Region are:

12/14/2016
Health Canada Approves CSL Behring’s AFSTYLA for the Treatment of Hemophilia A
Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A. More.

08/19/2016
CSL Canada is supporting “Missing Type” campaign.
Our web site does have missing letters, join the Canadian Blood Services “Missing Type” campaign. More.

05/16/2016
CSL Behring Commemorates 2016 hae day :-) with Partnerships, Sponsorships and Hereditary Angioedema Awareness Events
CSL Behring joins the global HAE community today in recognition of the fifth annual hae day :-), an initiative led by HAEi, the international patient organization for C1-inhibitor deficiency, along with the support of its national member organizations, including the US Hereditary Angioedema Association (HAEA). More.